The outlook for prevention and treatment of infections due to Pseudomonas aeruginosa.

L. S. Young, R. P. Wenzel, L. D. Sabath, M. Pollack, J. E. Pennington, R. Platt

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Control measures based on careful hospital surveillance are aimed primarily at minimizing environmental sources of Pseudomonas aeruginosa. Other important aspects of epidemiologic control include aggressive evaluation of outbreaks and limitation of antimicrobial use. Potent new antimicrobial chemotherapy has been developed, with most new agents of the beta-lactam and aminoglycoside classes. In spite of these developments, the likelihood of drug resistance seems great and the search for novel compounds continues. Of greatest appeal are approaches that augment host defences. Replacement or supplementation of circulating phagocytic cells is conceptually attractive, but this approach has encountered major technical problems and complications. More recently, there has been important progress in developing immunologic approaches aimed at augmenting circulating antibodies. Development of monoclonal antibodies and new methods for preparing hyperimmune globulins has produced forms of intervention that must be tested by clinical trials, but not all patients may benefit from augmentation of circulating antibodies to P. aeruginosa.
Original languageUndefined/Unknown
Pages (from-to)S769-S774
JournalReviews of Infectious Diseases
Volume6
Issue numberSuppl 3
StatePublished - 1984

Keywords

  • Anti-Bacterial Agents/pd [Pharmacology]
  • Anti-Bacterial Agents/tu [Therapeutic Use]
  • Antibodies, Bacterial
  • Clinical Trials as Topic
  • Cross Infection/pc [Prevention & Control]
  • Drug Resistance, Microbial
  • Humans
  • Immunization
  • Immunization, Passive
  • Lactams
  • Pseudomonas Infections/dt [Drug Therapy]
  • Pseudomonas Infections/pc [Prevention & Control]
  • Pseudomonas Infections/th [Therapy]
  • Pseudomonas aeruginosa/de [Drug Effects]
  • Pseudomonas aeruginosa/im [Immunology]

Cite this

Young, L. S., Wenzel, R. P., Sabath, L. D., Pollack, M., Pennington, J. E., & Platt, R. (1984). The outlook for prevention and treatment of infections due to Pseudomonas aeruginosa. Reviews of Infectious Diseases, 6(Suppl 3), S769-S774.

The outlook for prevention and treatment of infections due to Pseudomonas aeruginosa. / Young, L. S.; Wenzel, R. P.; Sabath, L. D.; Pollack, M.; Pennington, J. E.; Platt, R.

In: Reviews of Infectious Diseases, Vol. 6, No. Suppl 3, 1984, p. S769-S774.

Research output: Contribution to journalArticle

Young, LS, Wenzel, RP, Sabath, LD, Pollack, M, Pennington, JE & Platt, R 1984, 'The outlook for prevention and treatment of infections due to Pseudomonas aeruginosa.', Reviews of Infectious Diseases, vol. 6, no. Suppl 3, pp. S769-S774.
Young LS, Wenzel RP, Sabath LD, Pollack M, Pennington JE, Platt R. The outlook for prevention and treatment of infections due to Pseudomonas aeruginosa. Reviews of Infectious Diseases. 1984;6(Suppl 3):S769-S774.
Young, L. S. ; Wenzel, R. P. ; Sabath, L. D. ; Pollack, M. ; Pennington, J. E. ; Platt, R. / The outlook for prevention and treatment of infections due to Pseudomonas aeruginosa. In: Reviews of Infectious Diseases. 1984 ; Vol. 6, No. Suppl 3. pp. S769-S774.
@article{b7749e3dc6ac41baa9350bbce4cb233e,
title = "The outlook for prevention and treatment of infections due to Pseudomonas aeruginosa.",
abstract = "Control measures based on careful hospital surveillance are aimed primarily at minimizing environmental sources of Pseudomonas aeruginosa. Other important aspects of epidemiologic control include aggressive evaluation of outbreaks and limitation of antimicrobial use. Potent new antimicrobial chemotherapy has been developed, with most new agents of the beta-lactam and aminoglycoside classes. In spite of these developments, the likelihood of drug resistance seems great and the search for novel compounds continues. Of greatest appeal are approaches that augment host defences. Replacement or supplementation of circulating phagocytic cells is conceptually attractive, but this approach has encountered major technical problems and complications. More recently, there has been important progress in developing immunologic approaches aimed at augmenting circulating antibodies. Development of monoclonal antibodies and new methods for preparing hyperimmune globulins has produced forms of intervention that must be tested by clinical trials, but not all patients may benefit from augmentation of circulating antibodies to P. aeruginosa.",
keywords = "Anti-Bacterial Agents/pd [Pharmacology], Anti-Bacterial Agents/tu [Therapeutic Use], Antibodies, Bacterial, Clinical Trials as Topic, Cross Infection/pc [Prevention & Control], Drug Resistance, Microbial, Humans, Immunization, Immunization, Passive, Lactams, Pseudomonas Infections/dt [Drug Therapy], Pseudomonas Infections/pc [Prevention & Control], Pseudomonas Infections/th [Therapy], Pseudomonas aeruginosa/de [Drug Effects], Pseudomonas aeruginosa/im [Immunology]",
author = "Young, {L. S.} and Wenzel, {R. P.} and Sabath, {L. D.} and M. Pollack and Pennington, {J. E.} and R. Platt",
year = "1984",
language = "Undefined/Unknown",
volume = "6",
pages = "S769--S774",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "Suppl 3",

}

TY - JOUR

T1 - The outlook for prevention and treatment of infections due to Pseudomonas aeruginosa.

AU - Young, L. S.

AU - Wenzel, R. P.

AU - Sabath, L. D.

AU - Pollack, M.

AU - Pennington, J. E.

AU - Platt, R.

PY - 1984

Y1 - 1984

N2 - Control measures based on careful hospital surveillance are aimed primarily at minimizing environmental sources of Pseudomonas aeruginosa. Other important aspects of epidemiologic control include aggressive evaluation of outbreaks and limitation of antimicrobial use. Potent new antimicrobial chemotherapy has been developed, with most new agents of the beta-lactam and aminoglycoside classes. In spite of these developments, the likelihood of drug resistance seems great and the search for novel compounds continues. Of greatest appeal are approaches that augment host defences. Replacement or supplementation of circulating phagocytic cells is conceptually attractive, but this approach has encountered major technical problems and complications. More recently, there has been important progress in developing immunologic approaches aimed at augmenting circulating antibodies. Development of monoclonal antibodies and new methods for preparing hyperimmune globulins has produced forms of intervention that must be tested by clinical trials, but not all patients may benefit from augmentation of circulating antibodies to P. aeruginosa.

AB - Control measures based on careful hospital surveillance are aimed primarily at minimizing environmental sources of Pseudomonas aeruginosa. Other important aspects of epidemiologic control include aggressive evaluation of outbreaks and limitation of antimicrobial use. Potent new antimicrobial chemotherapy has been developed, with most new agents of the beta-lactam and aminoglycoside classes. In spite of these developments, the likelihood of drug resistance seems great and the search for novel compounds continues. Of greatest appeal are approaches that augment host defences. Replacement or supplementation of circulating phagocytic cells is conceptually attractive, but this approach has encountered major technical problems and complications. More recently, there has been important progress in developing immunologic approaches aimed at augmenting circulating antibodies. Development of monoclonal antibodies and new methods for preparing hyperimmune globulins has produced forms of intervention that must be tested by clinical trials, but not all patients may benefit from augmentation of circulating antibodies to P. aeruginosa.

KW - Anti-Bacterial Agents/pd [Pharmacology]

KW - Anti-Bacterial Agents/tu [Therapeutic Use]

KW - Antibodies, Bacterial

KW - Clinical Trials as Topic

KW - Cross Infection/pc [Prevention & Control]

KW - Drug Resistance, Microbial

KW - Humans

KW - Immunization

KW - Immunization, Passive

KW - Lactams

KW - Pseudomonas Infections/dt [Drug Therapy]

KW - Pseudomonas Infections/pc [Prevention & Control]

KW - Pseudomonas Infections/th [Therapy]

KW - Pseudomonas aeruginosa/de [Drug Effects]

KW - Pseudomonas aeruginosa/im [Immunology]

M3 - Article

VL - 6

SP - S769-S774

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - Suppl 3

ER -